ArticleScience (New York, N.Y.)2019
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 1 pooled it
11.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 1 synthesis or guideline pooled it, 273 citations in OpenAlex.
- Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2022Pooled it
- Carbohydrate antigen 72-4 and tumor-associated glycoprotein 72 - tumor marker: Past, present and future.World journal of gastrointestinal pathophysiology · 2026Review
- A controllable glycosyl molecularly imprinted strategy on MOF nanozyme for high-specificity colorimetric detection of CA19-9.Analytical and bioanalytical chemistry · 2026Article
- SIGLEC12 Predicts Prognosis and Chemotherapeutic Vulnerability in Patients with Pancreatic Cancer.Annals of surgical oncology · 2026Article
- From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O-GalNAc Glycosylation in Cancer.Chemical reviews · 2026Review
- Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis.Cell stem cell · 2026Article
- Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer Surgery.Annals of surgical oncology · 2026Article
- Cancer-associated alterations in O-GalNAc glycosylation.Glycobiology · 2026Review
- Immune implications and therapeutic opportunities of tumor glycosylation.Nature cancer · 2026Review
- Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas: current understanding and perspectives on malignant progression.Journal of gastroenterology · 2026Review
- A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Observational
- Engineering a glycosyl-imprinted nanozyme with a dual-ligand Ce-MOF for the selective and sensitive colorimetric sensing of CA19-9.Mikrochimica acta · 2026Article
- CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
- Association between serum carbohydrate antigen 199 levels and diabetic kidney disease in patients with type 2 diabetes: a retrospective cross-sectional study from Northwest China.BMC endocrine disorders · 2026Article
- Metabolic Salvage and Acyl-chain Remodeling Support Glycosphingolipid Synthesis within the PDAC Tumor Microenvironment.bioRxiv : the preprint server for biology · 2026Article
- Myofibroblasts Induce Neuroplasticity to Promote Pancreatic Inflammation and Cancer Progression.Cancer discovery · 2026Article
- Appendiceal Adenocarcinoma Cytoreduction Outcomes and Perioperative Serum Tumor Marker Levels.JAMA network open · 2026Article
- Integrative Approach to Develop and Characterize Antibodies against the Cancer-Associated Antigen Sialyl Lewis A (CA 19-9).JACS Au · 2026Article
- Review
- CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation.bioRxiv : the preprint server for biology · 2026Article
122 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
28 authors at 9 institutions in 2 countries.
Dannielle D EngleCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0003-1876-7675
Hervé TiriacCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0001-5039-6750
Keith D RiveraCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Arnaud PommierCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0002-5500-5453
Sean WhalenGladstone Institutes, San Francisco, CA 94158, USA.ORCID 0000-0002-6648-3610
Tobiloba E OniCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0002-6916-3380
Brinda AlagesanCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0001-7085-0260
Eun Jung LeeCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Melissa A YaoCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0002-2274-6925
Matthew S LucitoCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Benjamin SpielmanCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Brandon Da SilvaCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Christina SchoepferCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Kevin WrightCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.
Brianna CreightonCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0001-6495-3431
Lauren AfinowiczCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0002-2319-4210
Kenneth H YuDavid M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-4774-2672
Robert GrützmannDepartment of Surgery, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.
Daniela AustInstitute for Pathology, Universitätsklinikum Dresden, 01307 Dresden, Germany.ORCID 0000-0002-4867-8852
Phyllis A GimottyDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Katherine S PollardGladstone Institutes, San Francisco, CA 94158, USA.
Ralph H HrubanSidney Kimmel Cancer Center, The Sol Goldman Pancreatic Cancer Research Center, and Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.ORCID 0000-0003-4554-5672
Michael G GogginsSidney Kimmel Cancer Center, The Sol Goldman Pancreatic Cancer Research Center, and Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA.ORCID 0000-0002-4286-2296
Christian PilarskyDepartment of Surgery, Universitätsklinikum Erlangen, 91054 Erlangen, Germany.ORCID 0000-0002-7968-3283
Youngkyu ParkCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0003-1169-6739
Darryl J PappinCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.ORCID 0000-0002-8981-8401
Michael A HollingsworthEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
David A TuvesonCold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA. dtuveson@cshl.edu.ORCID 0000-0002-8017-2712
Cold Spring Harbor Laboratory · USJohns Hopkins University · USUniversitätsklinikum Erlangen · DEGladstone Institutes · USKlinik und Poliklinik für Psychotherapie und Psychosomatik · DEMemorial Sloan Kettering Cancer Center · USQB3 · USUniversity of Nebraska Medical Center · USUniversity of Pennsylvania · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSingle-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9MVaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1MTissue CoreP50CA127297 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI HOLLINGSWORTH, MICHAEL A. · 2008 to 2018
$17.1MPancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9MUAB / UMN SPORE in Pancreatic CancerP50CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KLUG, CHRISTOPHER · 2010 to 2014
$11.1MProject 3: MUC16-Mediated Metabolic Reprograming Induces PC MetastasisP01CA217798 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI HOLLINGSWORTH, MICHAEL A. · 2018 to 2022
$8.1MNrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment ResponseR01CA188134 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2017 to 2021
$3.0M(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic CancerR01CA190092 · NCI · COLD SPRING HARBOR LABORATORY · PI TUVESON, DAVID A · 2014 to 2017
$2.2MPreclinical Models for Cancer Therapeutic DevelopmentR50CA211506 · NCI · COLD SPRING HARBOR LABORATORY · PI PARK, YOUNGKYU · 2016 to 2025
$2.1MIntegrated Translational Cancer Science CenterU10CA180944 · NCI · COLD SPRING HARBOR LABORATORY · PI BAKER, LAURENCE HOWARD, LIU, EDISON TAK-BUN · 2014 to 2018
$2.0MCSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training ProgramT32CA148056 · NCI · COLD SPRING HARBOR LABORATORY · PI TROTMAN, LLOYD C · 2011 to 2020
$1.8MNCI NIH HHS K99 CA204725NCI NIH HHS P01 CA217798NCI NIH HHS P20 CA192994NCI NIH HHS P20 CA192996NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS P30 CA045508NCI NIH HHS P50 CA101955NCI NIH HHS P50 CA127297NCI NIH HHS R00 CA204725NCI NIH HHS R01 CA188134NCI NIH HHS R01 CA190092NCI NIH HHS R50 CA211506NCI NIH HHS T32 CA148056NCI NIH HHS U01 CA210240NCI NIH HHS U10 CA180944NIH HHS S10 OD010580NIH HHS S10 OD018338
Abstract
Glycosylation alterations are indicative of tissue inflammation and neoplasia, but whether these alterations contribute to disease pathogenesis is largely unknown. To study the role of glycan changes in pancreatic disease, we inducibly expressed human fucosyltransferase 3 and β1,3-galactosyltransferase 5 in mice, reconstituting the glycan sialyl-Lewis
Indexed as
Acute DiseaseAnimalsCA-19-9 AntigenCarcinogenesisCarcinoma, Pancreatic DuctalCell Line, TumorChronic DiseaseErbB ReceptorsExtracellular Matrix ProteinsFucosyltransferasesGalactosyltransferasesGlycosylationHumansMiceMolecular Targeted TherapyPancreatic Neoplasms3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferaseB3GALT5 protein, humanCA-19-9 AntigenEfemp1 protein, mouseErbB ReceptorsExtracellular Matrix ProteinsFucosyltransferasesGalactosyltransferases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.